RXi Pharmaceuticals Corp. (NASDAQ:RXII) is a discovery-stage biopharmaceutical company. The company is pursuing the development and commercialization of proprietary therapeutics based on RNA interference (RNAi) for the treatment of human diseases.

RXi Pharma intends to put their initial focus on the treatment of neurological and metabolic diseases and cancer. RNAi is a naturally-occurring mechanism for the regulation of gene expression that has the potential to be harnessed to selectively inhibit certain genes that lead to disease.

Rxi Pharma was founded by world-leading researchers in the field of RNAi. Most notably, this includes Dr. Craig Mello, recipient of the 2006 Nobel Prize for Medicine for his co-discovery of RNAi. Dr. Mello and others will have presentations at the company’s first annual investor event. The event will be held on October 21, 2008 at 8:30 a.m. ET in New York City. A live webcast of the event will be available at the company’s website.

Let us hear your thoughts below: